February 28, 2018 / 12:14 PM / 6 months ago

BRIEF-Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1

Feb 28 (Reuters) - Bristol-Myers Squibb Co:

* HEAT BIOLOGICS - INTERIM RESULTS FROM PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BRISTOL-MYERS'S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB

* HEAT BIOLOGICS SAYS COMBINATION OF HS-110 AND NIVOLUMAB WAS WELL TOLERATED - SEC FILING

* HEAT BIOLOGICS - IN PHASE 2 CLINICAL TRIAL OF HS-110 AND NIVOLUMAB, OVERALL RESPONSES APPEARED DURABLE AND LONG LASTING‍​ Source text (bit.ly/2BTjnp7) Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below